Trial Profile
An Open-Label, Expanded Access Protocol of Cemiplimab in Patients With Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Who Are Not Candidates for Surgery
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Aug 2019
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 10 Oct 2018 Status changed from recruiting to completed.
- 12 Apr 2018 New trial record